Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-70, 429 and PF-03709270 · 1 trial · 1 indication
PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.
Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).
AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).
Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
PF-03709270 is an oral prodrug of CP-70,429. Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429. Cmax of CP-70429 following CP-70,429 intravenous dose was reported.
Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).
AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).
Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
| Arm | Type | Description |
|---|---|---|
| IV CP-70,429 and cross over to PF-03709270 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CP-70,429 and PF-03709270 | DRUG | Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg). |
Inclusion Criteria: Subjects must meet one of the following renal function categories: * Normal renal function (CLcr \>80 mL/min). * Mild renal impairment (CLcr \>50 and \<80 mL/min). * Moderate renal impairment (CLcr \>30 and \<50 mL/min). * Severe renal impairment (CLcr \<30 mL/min). Exclusion ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | - | Undisclosed |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | - | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | N/A | Undisclosed |
CP-70,429 and PF-03709270 is an investigational small molecule being developed by Pfizer for the treatment of pneumonia. It is currently in Phase 1 clinical development, meaning it is still being studied and has not been approved for use.
CP-70,429 and PF-03709270 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 1 clinical development for pneumonia.
CP-70,429 and PF-03709270 is in Phase 1 clinical development. It is an investigational drug for pneumonia and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial.
CP-70,429 and PF-03709270 has been studied in one completed Phase 1 clinical trial, identified as NCT00759564. This trial investigated the pharmacokinetics, safety, and tolerability of intravenous and oral forms of the compound in subjects with varying degrees of renal impairment and normal renal function.
Yes, CP-70,429 and PF-03709270 refer to the same investigational drug. The compound is being developed by Pfizer for the treatment of pneumonia and is currently in Phase 1 clinical development.